Platelet-Mediated NET Formation Exacerbates Ischemic Stroke Brain Injury

医学 中性粒细胞胞外陷阱 冲程(发动机) 血小板活化 血小板 内科学 脑缺血 缺血 缺血性中风 心脏病学 炎症 免疫学 机械工程 工程类
作者
Frederik Denorme,Irina Portier,Mark J. Cody,Ramesh Grandhi,Matthew D. Neal,Jennifer J. Majersik,Christian C. Yost,Robert A. Campbell
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 437-437 被引量:4
标识
DOI:10.1182/blood-2021-151423
摘要

Abstract Background: Ischemic stroke provokes a strong inflammatory response which has been shown to exacerbate ischemic stroke brain injury in mice and is associated with worse outcomes in ischemic stroke patients. Classic anti-inflammatory strategies have been unsuccessful in clinical trials for ischemic stroke, implying other mechanisms contribute to injurious inflammation in ischemic stroke. Immunothrombosis is the interplay between coagulation, platelet activation and the innate immune system leading to thrombosis. A critical component of immunothrombosis is the formation of neutrophil extracellular traps (NETs). In this study, we investigated mechanistic regulators of NET formation in stroke and if they contribute to ischemic stroke outcomes. Methods: Markers of immunothrombosis were assessed in plasma from ischemic stroke patients and healthy matched donors. Flow cytometry was used to characterize platelet and neutrophil function. For murine studies, we used male and female C57Bl/6 mice that were subjected to transient middle cerebral artery occlusion. Stroke outcomes were assessed 24 hours or 7 days after stroke using neurological and motor function testing as well as brain infarct size analysis. Results: Ischemic stroke patients had significantly increased plasma biomarkers of immunothrombosis including D-Dimers (coagulation), platelet factor 4 (platelet activation) and calprotectin (neutrophil activation). Moreover, specific markers of NET formation including citrullinated histone H3 (H3cit) and MPO-DNA complexes were significantly elevated in ischemic stroke patients. Interestingly, H3cit and MPO-DNA complexes positively correlated with worse stroke outcomes at discharge while they did not correlate with stroke severity at admission. Next, we observed increased plasma and platelet surface expressed high mobility group box 1 (HMGB1) in ischemic stroke patients compared to matched healthy controls. NETs were found in platelet-rich areas in ischemic stroke thrombi, and HMGB1 colocalized with platelets in ischemic stroke thrombi. Blocking platelet-derived HMGB1 in vitro prevented platelet-induced NET formation. Mechanistically, depleting platelets in mice reduced plasma HMGB1 levels as well as NET formation and improved outcomes after ischemic stroke. In contrast, depleting neutrophils did not affect plasma HMGB1 levels, but reduced plasma NETs and improved stroke outcomes. Treatment of mice with a competitive HMGB1 inhibitor (BoxA) reduced NET formation and improved stroke outcomes. Combined, these results imply a causative role for platelet-derived HMGB1 in mediating detrimental NET formation after ischemic stroke. Finally, as NETs appeared injurious in ischemic stroke, we investigated the therapeutic potential of a recently discovered neonatal NET inhibitory factor (nNIF). nNIF is a cleavage fragment of alpha-1-antitrypsin and specifically blocks NET formation in human and murine neutrophils without affecting other critical neutrophil functions such as chemotaxis or phagocytosis. Mice treated with nNIF had reduced brain and plasma NETs after stroke while cerebral neutrophil recruitment remained unaffected. The reduction in NET formation after stroke was associated with reduced neuronal apoptosis and smaller brain infarcts. Furthermore, nNIF treated mice had improved neurological and motor function and enhanced 7-day survival after ischemic stroke. Conclusions: These results support a pathological role for NETs in acute ischemic stroke and warrant further investigation into nNIF as a therapeutic to improve stroke outcomes. Disclosures Neal: Instrumentation Laboratories: Research Funding; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Haima Therapeutics: Membership on an entity's Board of Directors or advisory committees; Haemonetics: Honoraria, Research Funding.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被nnn采纳,获得30
1秒前
2秒前
酷波er的应助被tom采纳,获得10
2秒前
白衣完成签到,获得积分10
2秒前
2秒前
科目三的应助被虚心夏之采纳,获得10
3秒前
费谷槐完成签到 ,获得积分10
5秒前
科研通AI6.2的应助被红红采纳,获得10
5秒前
葛根完成签到,获得积分10
6秒前
安静代荷完成签到,获得积分10
6秒前
哼哼哈嘿完成签到,获得积分10
6秒前
Bear完成签到 ,获得积分10
7秒前
逆流沙完成签到,获得积分10
7秒前
7秒前
工艺纯化小天才完成签到 ,获得积分10
8秒前
8秒前
欢快的芹菜完成签到,获得积分10
8秒前
8秒前
8秒前
Sakura完成签到,获得积分10
8秒前
gy完成签到 ,获得积分10
8秒前
9秒前
六六发布了新的文献求助10
9秒前
swimming完成签到,获得积分10
9秒前
资明轩完成签到,获得积分10
9秒前
9秒前
xl的应助被啵啵采纳,获得10
10秒前
专注的尔槐完成签到,获得积分10
10秒前
迷人皮卡丘完成签到 ,获得积分10
10秒前
Lindsay发布了新的文献求助10
11秒前
12秒前
XwX关注了科研通微信公众号
12秒前
SFGGFT发布了新的文献求助10
12秒前
12秒前
无心的蓝发布了新的文献求助10
13秒前
奇迹行者完成签到,获得积分10
13秒前
w2503完成签到,获得积分10
14秒前
14秒前
swimming发布了新的文献求助10
15秒前
Jasper的应助被贪玩的一曲采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168163
求助须知:如何正确求助?哪些是违规求助? 9561243
关于积分的说明 21759855
捐赠科研通 7759477
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553757
邀请新用户注册赠送积分活动 2474496